Epidemiology of antibiotic resistance in Pseudomonas aeruginosa. Implications for empiric and definitive therapy
- PMID: 28882007
Epidemiology of antibiotic resistance in Pseudomonas aeruginosa. Implications for empiric and definitive therapy
Abstract
Pseudomonas aeruginosa is one of the major pathogens causing hospital-acquired infections. It can easily develop antibiotic resistance through chromosomal mutations or by horizontal acquisition of resistant determinants. The increasing prevalence of multi-drug-resistant (MDR) or extensively-drug-resistant (XDR) P. aeruginosa isolates is associated with the dissemination of the so-called high-risk-clones, such as ST175. Infections caused by MDR/XDR are a cause of concern as they compromise the selection of appropriate empiric and definitive antimicrobial treatments. Introduction of new antibiotics with potent activity against MDR/XDR P. aeruginosa opens new horizons in the treatment of these infections.
Similar articles
-
The increasing threat of Pseudomonas aeruginosa high-risk clones.Drug Resist Updat. 2015 Jul-Aug;21-22:41-59. doi: 10.1016/j.drup.2015.08.002. Epub 2015 Aug 10. Drug Resist Updat. 2015. PMID: 26304792 Review.
-
Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones.Antimicrob Agents Chemother. 2012 Dec;56(12):6349-57. doi: 10.1128/AAC.01388-12. Epub 2012 Oct 8. Antimicrob Agents Chemother. 2012. PMID: 23045355 Free PMC article.
-
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update.Int J Antimicrob Agents. 2020 Dec;56(6):106196. doi: 10.1016/j.ijantimicag.2020.106196. Epub 2020 Oct 9. Int J Antimicrob Agents. 2020. PMID: 33045347 Review.
-
Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance.J Infect. 2017 Feb;74(2):142-152. doi: 10.1016/j.jinf.2016.11.008. Epub 2016 Nov 16. J Infect. 2017. PMID: 27865895
-
Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa.Rev Esp Quimioter. 2019 Sep;32 Suppl 2(Suppl 2):32-34. Rev Esp Quimioter. 2019. PMID: 31475807 Free PMC article. Review.
Cited by
-
Antimicrobial Activity of Colistin Against Contemporary (2015 - 2017) P. aeruginosa and A. baumannii Isolates From a Chinese Surveillance Program.Front Microbiol. 2020 Sep 4;11:1966. doi: 10.3389/fmicb.2020.01966. eCollection 2020. Front Microbiol. 2020. PMID: 33013738 Free PMC article.
-
Liposomal Delivery of Newly Identified Prophage Lysins in a Pseudomonas aeruginosa Model.Int J Mol Sci. 2022 Sep 4;23(17):10143. doi: 10.3390/ijms231710143. Int J Mol Sci. 2022. PMID: 36077542 Free PMC article.
-
Bacterial Ghosts of Pseudomonas aeruginosa as a Promising Candidate Vaccine and Its Application in Diabetic Rats.Vaccines (Basel). 2022 Jun 7;10(6):910. doi: 10.3390/vaccines10060910. Vaccines (Basel). 2022. PMID: 35746518 Free PMC article.
-
Engineered Bacteriophages Containing Anti-CRISPR Suppress Infection of Antibiotic-Resistant P. aeruginosa.Microbiol Spectr. 2022 Oct 26;10(5):e0160222. doi: 10.1128/spectrum.01602-22. Epub 2022 Aug 16. Microbiol Spectr. 2022. PMID: 35972246 Free PMC article.
-
Prevalence, Appropriateness, and Outcomes of Colistin Use in Multidrug-Resistant Pseudomonas aeruginosa Infections: Insights from Hospital Data.Medicina (Kaunas). 2025 Jul 15;61(7):1275. doi: 10.3390/medicina61071275. Medicina (Kaunas). 2025. PMID: 40731904 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical